Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251326095. doi: 10.1177/10760296251326095. Epub 2025 Dec 25.
ABSTRACT
BackgroundSepsis-Induced Coagulopathy (SIC) is common complications of sepsis in intensive care unit (ICU) patients. It has a significant impact on the prognosis of patients with sepsis and is an important cause of death. However, there is no evidence for the use of Argatroban in SIC anticoagulant therapy.MethodA retrospective study was conducted based on data collected from patients with sepsis from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. SIC patients were screened according to SIC scores formulated by the International Society of Thrombosis and Hemostasis. Propensity score matching was used to match patients who received Argatroban with patients who did not receive Argatroban. Cox regression analysis was used to explore the correlation between Argatroban and SIC prognosis, and the hazard ratio was calculated. Finally, Kaplan-Meier curve was used to compare the survival rate between the two groups.OutcomeAfter PSM, 108 patients who received Argatroban were matched with 108 patients who did not receive Argatroban. In terms of outcomes, Argatroban admission to ICU was associated with a higher risk of death 30 days after ICU admission for SIC patients (HR = 1.800; 95%CI: 1.064∼3.043; P = .043) correlation.ConclusionArgatroban is not recommended for anticoagulant therapy in SIC patients.
PMID:41449917 | DOI:10.1177/10760296251326095